Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiotensin-converting enzyme inhibitors in left ventricular dysfunction

W D Linn1

  • 1Department of Medicine, Audie Murphy Veterans Administration Hospital, San Antonio, Texas 78284, USA.

Pharmacotherapy
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of antihypertensive medications among United States veterans newly diagnosed with hypertension.

Current medical research and opinion·2008
Same author

A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurements.

Pharmacotherapy·1997
Same author

Collaborative drug therapy management by pharmacists. American College of Clinical Pharmacy.

Pharmacotherapy·1997
Same author

Warfarin and aspirin after heart-valve replacement.

The New England journal of medicine·1994
Same author

Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation.

Pharmacotherapy·1992
Same author

The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

JAMA·1991
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Angiotensin-converting enzyme (ACE) inhibitors improve survival in heart failure patients by approximately 6 months and reduce hospitalizations. These life-prolonging drugs also benefit patients after myocardial infarction but remain underutilized by primary care providers.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are established treatments for chronic congestive heart failure.
  • Recent evidence supports their use in post-myocardial infarction patients.
  • Underutilization persists due to provider confusion regarding optimal patient selection.

Purpose of the Study:

  • To evaluate the impact of ACE inhibitors on morbidity and mortality in patients with chronic heart failure and acute myocardial infarction.
  • To clarify which patient subgroups benefit most from ACE inhibitor therapy.
  • To address the underutilization of ACE inhibitors in clinical practice.

Main Methods:

  • Systematic review and evaluation of randomized controlled trials.
  • Analysis of data on morbidity and mortality outcomes.

Related Experiment Videos

  • Assessment of ACE inhibitors' effects on survival and hospital admissions.

    • Main Results:

    • ACE inhibitors significantly improve survival in symptomatic congestive heart failure patients, offering an approximate 6-month survival benefit.
    • In asymptomatic systolic dysfunction, ACE inhibitors reduce heart failure-related hospital admissions.
    • All patients experiencing acute myocardial infarction show improved survival with ACE inhibitor use.

    Conclusions:

    • ACE inhibitors offer substantial survival benefits and reduce hospitalizations in various cardiovascular conditions.
    • Despite robust evidence, clinician reluctance to prescribe ACE inhibitors necessitates improved education on patient risk stratification and timely initiation of therapy.
    • Optimizing ACE inhibitor use can enhance patient quality of life and long-term outcomes.